CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 30, 2013	Dec. 31, 2012
Current assets
Cash	$ 1,927,226	$ 534,046
Prepaid drug product for testing	279,180	195,000
Other current assets	46,411	42,575
Total current assets	2,252,817	771,621
Other assets
Technology licenses - related party	2,500,374	2,500,374
Less Accumulated Amortization	(1,008,544)	(928,231)
Intangible Assets, Net (Excluding Goodwill), Total	1,491,830	1,572,143
TOTAL ASSETS	3,744,647	2,343,764
Current liabilities
Accounts payable	165,897	57,000
Accounts payable - related party	10,017	8,582
Accrued expense	4,892	137,662
Accrued expense - related party	37,050	26,000
Accrued license payments - related party	50,000	100,000
Total current liabilities	267,856	329,244
Long term debt	0	0
TOTAL LIABILITIES	267,856	329,244
Shareholders' Equity
Preferred Stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding	0	0
Common Stock, $.001 par value, 200,000,000 shares authorized 75,380,214 and 62,219,050 shares issued and outstanding as of 6/30/13 and 12/31/12, respectively	75,380	62,218
Additional paid in capital	16,615,942	13,321,075
Additional paid in capital for shares to be issued	0	762,510	[1]
Accumulated deficit during development stage	(13,214,531)	(12,131,283)
Total shareholders' equity	3,476,791	2,014,520
TOTAL LIABILITIES & SHAREHOLDERS' EQUITY	$ 3,744,647	$ 2,343,764

[1] Represents 2,541,700 shares of common stock